PALO ALTO, Calif., Oct. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted ...
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will ...
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other ...
Wall Street Analysts have high expectations for Eiger. Eiger has a modest pipeline. Expect near term data to impact the stock in a big way. This is my second Eiger BioPharmaceuticals (EIGR) article ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results